Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?

Barchart
Apri Barchart
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?

Headquartered in Cambridge, Massachusetts, Biogen Inc. (BIIB) is a biotechnology company focused on developing and commercializing treatments for neurological, neurodegenerative, and other serious diseases. Founded in 1978, its portfolio includes therapies for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, and amyotrophic lateral sclerosis (ALS), among others. Biogen also works with pharmaceutical and biotechnology partners to advance new treatments through research and development, strengthening its pipeline and expanding its presence across global healthcare markets. Its market capitalization currently stands at around $36.5 billion.

Shares of this leading biotechnology company have notably outperformed the broader market over the past year. BIIB stock has surged 47.2% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 8%. The rally has continued in 2026, with shares rising 40.4%, well ahead of the index’s 4.8% advance.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

BIIB has also beaten its industry peers. The iShares Neuroscience and Healthcare ETF (IBRN) has gained 10.3% over the past year and just 1% so far in 2026. Clearly, Biogen has been having a much stronger run than both the broader market and its sector peers.

www.barchart.com

Biogen’s shares have been enjoying a strong rally, hitting a 52-week high of $261 on Nov. 9. The momentum comes from improving business performance, pipeline progress, and growing Wall Street optimism. Its Q3 2026 revenue climbed 11% year over year (YOY) to $2.8 billion, while its growth portfolio expanded 49%, now accounting for 63% of core pharmaceutical revenue. Rare disease sales also rose 27%, although multiple sclerosis revenue declined 13%. The Apellis acquisition added $242.8 million in sales.

Meanwhile, encouraging Phase 3 lupus data for its investigational drug dapirolizumab pegol, developed with UCB, further strengthened investor confidence.

For the current fiscal year, ending in December, analysts expect Biogen’s EPS to decline 18.5% to $12.46 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.

Among the 34 analysts covering BIIB stock, the consensus is a “Moderate Buy.” That’s based on 22 “Strong Buy” ratings, two “Moderate Buys,” and 10 “Holds.”

www.barchart.com

This configuration is slightly more bullish than a month ago when 21 analysts suggested “Strong Buy” ratings. 

Piper Sandler recently raised its price target on BIIB stock to $305 from $245, maintaining an “Overweight” rating. The brokerage firm sees room for further gains, supported by a stable core business and a more diversified revenue base following the Apellis acquisition, which also reduces long-term patent-expiry risks. Piper also highlighted its immunology pipeline and upcoming clinical milestones. However, it views litifilimab’s Phase III lupus programs differently, considering systemic lupus higher-risk but higher-reward, while the cutaneous lupus study has better odds of success.

The mean price target of $269.56 represents 9.1% upside potential from BIIB’s current price. The Street-high price target of $350 suggests that the stock could rally as much as 41.6%.


On the date of publication, Sristi Suman Jayaswal did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Is Serve Robotics Stock’s 669% Options Payout a Bull Trap? You Might Be Shocked By the Answer. Ahead of Sidus Space Earnings, Here's What Barchart Data Says Comes Next for SIDU Stock Palo Alto Networks Stock Soars on Strong FCF Guidance - Any More Upside Left in PANW? 2 Stocks to Buy on a Potential U.S. Ban on Some Chinese Tech